iGene to Participate in 2023 BIO USA... Introducing mRNA Vaccine Technology
iGene announced on the 22nd that it will participate in '2023 BIO USA,' the world's largest pharmaceutical and biotech convention, held in Boston, USA, from the 5th to the 9th of next month.
iGene will join the Korean Pavilion booth, supported by the Ministry of Trade, Industry and Energy and organized by the Korea Bio Association and the Korea Trade-Investment Promotion Agency (KOTRA), and plans to conduct partnering with over 20 global pharmaceutical companies during the event.
At this event's partnering sessions, iGene plans to promote the global commercialization of mRNA-based vaccine technology using the cationic liposome-structured messenger ribonucleic acid (mRNA) delivery system "EG-R" and recombinant shingles vaccine (EG-HZ) technology containing a cationic liposome-structured immune adjuvant. iGene is developing a COVID-19 vaccine using EG-R that can be stored refrigerated and has significantly reduced side effects. Clinical Phase 2a booster trials for the first virus strain, Wuhan strain, and Omicron variant-specific vaccines, 'EG-COVID' and 'EG-COVARo,' are currently underway in Australia.
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "I Will Give Them a Chance for Self-Examination": Chinese Scientific Community Shaken by Influencer's Preemptive Whistleblowing
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
An iGene representative stated, "At this BIO USA event, we will focus not only on introducing iGene's COVID-19 vaccine utilizing our delivery system but also on presenting 'iPT,' the mRNA-based personalized cancer vaccine system developed by Renaim, which is conducting cancer vaccine research and development using iGene's delivery system."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.